Free tool
FAERS Monitor: Betamethasone Valerate
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 018866 or its brand name (Betamethasone Valerate, Betamethasone Valerate). Reports on generic versions are filed under their own applications.
Reports
4,595
Serious
4,066
88% of reports
Hospitalization
1,341
Death reported
240
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,081
- macular degeneration644
- pain611
- off label use501
- pyrexia428
- malaise424
- nausea422
- headache416
- weight decreased416
- pruritus353
- rash338
- abdominal pain308
- erythema308
- vomiting302
- dyspnoea298
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 13 |
| 2005 | 13 |
| 2006 | 15 |
| 2007 | 17 |
| 2008 | 21 |
| 2009 | 25 |
| 2010 | 39 |
| 2011 | 56 |
| 2012 | 52 |
| 2013 | 85 |
| 2014 | 127 |
| 2015 | 179 |
| 2016 | 213 |
| 2017 | 189 |
| 2018 | 209 |
| 2019 | 345 |
| 2020 | 350 |
| 2021 | 570 |
| 2022 | 479 |
| 2023 | 499 |
| 2024 | 427 |
| 2025 | 388 |
| 2026 | 284 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,564 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| macular degenerationSignal | 644 | 260.8 | 242.2 | 157,535 |
| erythemaSignal | 308 | 6.9 | 6.2 | 1,551 |
| weight decreasedSignal | 416 | 6.8 | 6.2 | 2,089 |
| abdominal painSignal | 308 | 6.1 | 5.4 | 1,311 |
| pyrexiaSignal | 428 | 5.7 | 5.2 | 1,666 |
| painSignal | 611 | 4.6 | 4.2 | 1,742 |
| malaiseSignal | 424 | 4.4 | 4.0 | 1,145 |
| pruritusSignal | 353 | 4.2 | 3.8 | 875 |
| drug ineffectiveSignal | 1,081 | 3.8 | 3.6 | 2,328 |
| rashSignal | 338 | 3.6 | 3.2 | 630 |
| headacheSignal | 416 | 3.0 | 2.8 | 584 |
| vomitingSignal | 302 | 2.9 | 2.6 | 394 |
| off label useSignal | 501 | 2.6 | 2.4 | 522 |
| nauseaSignal | 422 | 2.4 | 2.2 | 371 |
| dyspnoeaSignal | 298 | 2.4 | 2.2 | 251 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.